Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ANI Pharmaceuticals Inc (NASDAQ:ANIP)

68.26
Delayed Data
As of Sep 27
 +2.90 / +4.44%
Today’s Change
26.80
Today|||52-Week Range
70.92
+51.27%
Year-to-Date
Amgen's Multiple Myeloma Drug Kyprolis Fails in Phase III
7:54am / Zacks.com - Paid Partner Content
CoLucid Pharmaceuticals (CLCD) in Focus: Stock Jumps 7.4%
Sep 20 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica
Sep 27 / Zacks.com - Paid Partner Content
Idera Pharmaceuticals in Focus: Stock Adds 8.8% in Session
Sep 20 / Zacks.com - Paid Partner Content
Amarin Corporation (AMRN) Looks Good: Stock Adds 6.1% in Session
Sep 27 / Zacks.com - Paid Partner Content
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Sep 19 / Zacks.com - Paid Partner Content
Achillion, J&J HCV Triple Combination Drug Data Presented
Sep 26 / Zacks.com - Paid Partner Content
AstraZeneca Diabetes Drug Combination Positive in Phase III
Sep 19 / Zacks.com - Paid Partner Content
AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb
Sep 26 / Zacks.com - Paid Partner Content
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Sep 19 / Zacks.com - Paid Partner Content
Strength Seen in NewLink Genetics (NLNK): Stock Jumps 5%
Sep 26 / Zacks.com - Paid Partner Content
Eli Lilly (LLY) Gets Favorable CHMP Opinion for Olaratumab
Sep 19 / Zacks.com - Paid Partner Content
BioTime (BTX) Shows Strength: Stock Adds 5.9% in Session
Sep 26 / Zacks.com - Paid Partner Content
Novartis (NVS) Presents Positive Data on Cardiovascular Drug
Sep 19 / Zacks.com - Paid Partner Content
Ligand Inks CNS License Agreement with Seelos Therapeutics
Sep 23 / Zacks.com - Paid Partner Content
Halozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9%
Sep 19 / Zacks.com - Paid Partner Content
Zacks.com featured highlights: ANI Pharmaceuticals, Stoneridge, Cooper-Standard Holdi...
Sep 23 / Zacks.com - Paid Partner Content
Masimo PVI: Efficient Predictor for Fluid Optimization
Sep 16 / Zacks.com - Paid Partner Content
7 Stocks Near 52-Week Highs Worth Betting On
Sep 22 / Zacks.com - Paid Partner Content
Qiagen: Molecular Diagnostics & Expansion Plans on Track
Sep 16 / Zacks.com - Paid Partner Content
The Medicines Co. to Get BARDA Funding for Infection Drugs
Sep 22 / Zacks.com - Paid Partner Content
Teva/Intel Tie up for Huntington's Disease Technology Platform
Sep 16 / Zacks.com - Paid Partner Content
AstraZeneca Withdraws Cediranib Marketing Application in EU
Sep 22 / Zacks.com - Paid Partner Content
Novavax Tanks, RSV F Vaccine Disappoints in Two Studies
Sep 16 / Zacks.com - Paid Partner Content
Dicerna Pharmaceuticals (DRNA) Worth a Look: Stock Up 6%
Sep 22 / Zacks.com - Paid Partner Content
Merck/Pfizer Diabetes Drug Ertugliflozin Positive in Phase III
Sep 16 / Zacks.com - Paid Partner Content
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Sep 21 / Zacks.com - Paid Partner Content
Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel
Sep 15 / Zacks.com - Paid Partner Content
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Sep 21 / Zacks.com - Paid Partner Content
Sarepta Shares Soar on News of Key Drug Critic FDA Exit
Sep 15 / Zacks.com - Paid Partner Content
Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
Sep 21 / Zacks.com - Paid Partner Content
Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi (revised)
Sep 15 / Zacks.com - Paid Partner Content
Bristol-Myers Opdivo's Regulatory Application Validated in EU
Sep 21 / Zacks.com - Paid Partner Content
Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Sep 15 / Zacks.com - Paid Partner Content
Adamas (ADMS) Parkinson's Disease Drug Positive in Phase III
Sep 21 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Presents Data on Obesity Drug Saxenda
Sep 15 / Zacks.com - Paid Partner Content
ProQR Therapeutics (PRQR) Catches Eye: Stock Rises 8.2%
Sep 21 / Zacks.com - Paid Partner Content
Roche Ocrevus Positive in Phase III Multiple Sclerosis Trials
Sep 15 / Zacks.com - Paid Partner Content
Regenxbio (RGNX) Worth Watching: Stock Adds 5.3% in Session
Sep 21 / Zacks.com - Paid Partner Content
Bayer to Boost Agriculture Suite with $66B Monsanto Buyout
Sep 15 / Zacks.com - Paid Partner Content
Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study
Sep 20 / Zacks.com - Paid Partner Content
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Sep 15 / Zacks.com - Paid Partner Content
BioDelivery Bunavail Gets Better Managed Care Positioning
Sep 20 / Zacks.com - Paid Partner Content
Aerie (AERI) Stock Up on Positive Phase III Data on Roclatan
Sep 15 / Zacks.com - Paid Partner Content
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Sep 20 / Zacks.com - Paid Partner Content
Asterias Biotherapeutics (AST) Catches Eye: Stock Jumps 6%
Sep 15 / Zacks.com - Paid Partner Content
Bayer (BAYRY) Strives for Increased Sales & Earnings Growth
Sep 20 / Zacks.com - Paid Partner Content
Allergan to Buy Vitae Pharma to Boost Dermatology Suite
Sep 15 / Zacks.com - Paid Partner Content
Cara Therapeutics (CARA) Catches Eye: Stock Rises 5.7%
Sep 20 / Zacks.com - Paid Partner Content
ANI Pharmaceuticals (ANIP) Sees Hammer Chart Pattern; Time to Buy?
Sep 14 / Zacks.com - Paid Partner Content